Advertisement
Research Article

What Can We Learn from the Evolution of Protein-Ligand Interactions to Aid the Design of New Therapeutics?

  • Alicia P. Higueruelo mail,

    alicia@cryst.bioc.cam.ac.uk

    Affiliation: Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

    X
  • Adrian Schreyer,

    Affiliation: Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

    X
  • G. Richard J Bickerton,

    Affiliation: Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

    Current address: Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, United Kingdom

    X
  • Tom L. Blundell,

    Affiliation: Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

    X
  • Will R. Pitt

    Affiliations: Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom, UCB Pharma, Slough, United Kingdom

    X
  • Published: December 11, 2012
  • DOI: 10.1371/journal.pone.0051742

About the Authors

Alicia P. Higueruelo, Adrian Schreyer, G. Richard J Bickerton, Tom L. Blundell, Will R. Pitt
Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
Will R. Pitt
UCB Pharma, Slough, United Kingdom

Corresponding Author

Email: alicia@cryst.bioc.cam.ac.uk

Competing Interests

WRP is an employee of UCB Pharma. However, the work was carried out while he was seconded to the University of Cambridge and he has no competing interests in the material in this manuscript. Therefore this does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The authors have declared that no other competing interests exist.

Author Contributions

Conceived and designed the experiments: APH TLB WRP. Performed the experiments: APH. Analyzed the data: APH. Contributed reagents/materials/analysis tools: AS GRJB. Wrote the paper: APH TLB WRP. Reviewed and edited the final version of the manuscript: APH AS GRJB TLB WRP.